오메가-3 지방산(EPA/DHA) 관련 궤양성 대장염(UC)
C 근거 소규모 연구에서의 근거는 제한적이지만, 일부 긍정적인 신호가 존재합니다.UC 관해 유지에 혼재된 결과를 보입니다. 일부 메타분석은 완만한 유익을 보이나 다른 연구는 유의한 효과가 없습니다. EPA가 DHA보다 더 유익할 수 있습니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Domega\u002D3\u002Dfatty\u002Dacids\u0026condition\u003Dibd\u002Dulcerative\u002Dcolitis';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
UC 관해 유지에 혼재된 결과를 보입니다. 일부 메타분석은 완만한 유익을 보이나 다른 연구는 유의한 효과가 없습니다. EPA가 DHA보다 더 유익할 수 있습니다.
Key Study Findings
Review
Diet in Ulcerative Colitis: A Narrative Review of Its Role in Pathogenesis and Treatment.
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: patients with ulcerative colitis
Review
Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit.
Dose: None
vs: None
Outcome: IBD microbiota modulation and immune regulation
효과: None
None
대상 집단: IBD patients (review of nutritional interventions)
Review
Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review.
Dose: None
vs: None
Outcome: Athletic performance and nutritional optimization
효과: None
None
대상 집단: Vegan athletes (narrative review)
Review
From Evidence to Practice: A Narrative Framework for Integrating the Mediterranean Diet into Inflammatory Bowel …
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: None
Other
Interaction between diet and genetics in patients with inflammatory bowel disease.
Dose: None
vs: None
Outcome: Diet-genetics interaction in IBD
효과: None
None
대상 집단: IBD patients (editorial commentary)
Review
Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian …
Dose: None
vs: None
Outcome: Colitis severity
효과: None
None
대상 집단: Crohn's disease patients
Key Statistics
8
연구
1000
참여자
↔
Mixed
C
등급
Referenced Papers
Digestive diseases and …
2026
1 인용
Nutrients
2025
9 인용
Semergen
2025
4 인용
Current nutrition reports
2025
3 인용
Autoimmunity reviews
2024
12 인용
World journal of …
2024
Metabolites
2023
13 인용
Association between dietary acid load and the odds of ulcerative colitis: a case-control study.
Other
Scientific reports
2023
1 인용
Nutrients
2022
66 인용
Nutrients
2022
61 인용
Journal of medicinal …
2022
8 인용
Foods (Basel, Switzerland)
2021
96 인용
Nutrients
2021
27 인용
Scientific reports
2020
56 인용
Therapeutic advances in …
2020
21 인용
Redox modulatory protective effects of ω-3 fatty acids rich fish oil against experimental colitis.
Other
Toxicology mechanisms and …
2019
33 인용
Nutrients
2019
24 인용
Gastroenterology clinics of …
2018
67 인용
International journal of …
2017
143 인용
Medical principles and …
2017
45 인용
Ugeskrift for laeger
2017
Annals of gastroenterology
2016
80 인용
European journal of …
2016
79 인용
Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis.
Review
Current pharmaceutical design
2016
32 인용
Clinics in dermatology
2016
19 인용
World journal of …
2014
36 인용
World journal of …
2014
25 인용
Alimentary pharmacology & …
2013
128 인용
Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view.
Systematic Review
World journal of …
2013
56 인용
The British journal …
2012
145 인용
Dietary supplements for established atopic eczema.
Meta-Analysis
The Cochrane database …
2012
130 인용
World journal of …
2012
113 인용
Frontline gastroenterology
2012
20 인용
Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature.
Systematic Review
The American journal …
2011
946 인용
Inflammatory bowel diseases
2011
195 인용
Nutrition in clinical …
2011
1 인용
JRSM short reports
2010
11 인용
Inflammatory bowel diseases
2008
77 인용
The Cochrane database …
2007
118 인용
Journal of food …
2007
49 인용
Nutrition (Burbank, Los …
2003
189 인용
Nutricion hospitalaria
2003
Journal of the …
2002
2016 인용
Nutrition (Burbank, Los …
2000
64 인용
Drugs
1998
99 인용
The American journal …
1998
84 인용
Bailliere's clinical gastroenterology
1997
26 인용
Langenbecks Archiv fur …
1995
3 인용
The American journal …
1992
260 인용
The American journal …
1991
2278 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 1,000-2,000 mg combined EPA/DHA per day
- ibdsupport:
- 2,000-4,000 mg/day combined EPA/DHA (higher EPA ratio may be more beneficial)
상한량: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Neutral | -- |
| None | -- | Neutral | -- |
| 95% | -- | Mixed | -- |
| 95% | -- | Mixed | 124 |
권장 복용 시간: With meals containing fat for better absorption
Safety & Side Effects
보고된 부작용
- ⚠ Fishy aftertaste and burping
- ⚠ Mild gastrointestinal discomfort (nausea, diarrhea)
- ⚠ Potential increased bleeding time at very high doses (>3 g/day)
- ⚠ May lower blood pressure slightly
알려진 상호작용
- ● Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
- ● Blood pressure medications (additive hypotensive effect)
- ● Orlistat (may reduce omega-3 absorption)
- ● Cyclosporine (fish oil may reduce cyclosporine nephrotoxicity but monitor levels)
일일 최대 섭취 허용량: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 오메가-3 지방산(EPA/DHA) help with 궤양성 대장염(UC)?
Based on 8 studies with 1,000 participants, there is limited but promising evidence that 오메가-3 지방산(EPA/DHA) may support 궤양성 대장염(UC) management. Our evidence grade is C (Some Evidence).
How much 오메가-3 지방산(EPA/DHA) should I take for 궤양성 대장염(UC)?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined EPA/DHA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 오메가-3 지방산(EPA/DHA)?
Reported side effects may include Fishy aftertaste and burping, Mild gastrointestinal discomfort (nausea, diarrhea), Potential increased bleeding time at very high doses (>3 g/day), May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 오메가-3 지방산(EPA/DHA) and 궤양성 대장염(UC)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 8 peer-reviewed studies with 1,000 total participants. The overall direction of effect is mixed.
Related Evidence
관련 다른 성분: 궤양성 대장염(UC)
오메가-3 지방산(EPA/DHA) 다른 건강 상태에 대한 근거
References
- [1] Fares Jamal et al.. Dig Dis Sci. 2026. Diet in Ulcerative Colitis: A Narrative Review of Its Role in Pathogenesis and Treatment. doi:10.1007/s10620-025-09387-z PubMed
- [2] Riya Gautam Naik et al.. Nutrients. 2025. From Evidence to Practice: A Narrative Framework for Integrating the Mediterranean Diet into Inflammatory Bowel Disease Management. doi:10.3390/nu17030470 PubMed
- [3] D Fetarayani et al.. Semergen. 2025. Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit. doi:10.1016/j.semerg.2025.102575 PubMed
- [4] Álvaro Vergara A Nieto et al.. Curr Nutr Rep. 2025. Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review. doi:10.1007/s13668-025-00633-4 PubMed
- [5] Kimsor Hong et al.. Autoimmun Rev. 2024. Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian randomization analysis. doi:10.1016/j.autrev.2024.103651 PubMed
- [6] Daniéla Oliveira Magro et al.. World J Gastroenterol. 2024. Interaction between diet and genetics in patients with inflammatory bowel disease. doi:10.3748/wjg.v30.i12.1644 PubMed
- [7] Xiaojing Jia et al.. Metabolites. 2023. Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bowel Disease via Circulating Metabolites: A Mediation Mendelian Randomization Study. doi:10.3390/metabo13101041 PubMed
- [8] Mina Movahedian et al.. Sci Rep. 2023. Association between dietary acid load and the odds of ulcerative colitis: a case-control study. doi:10.1038/s41598-023-41069-6 PubMed
- [9] Ammar Hassanzadeh Keshteli et al.. Nutrients. 2022. Anti-Inflammatory Diet Prevents Subclinical Colonic Inflammation and Alters Metabolomic Profile of Ulcerative Colitis Patients in Clinical Remission. doi:10.3390/nu14163294 PubMed
- [10] Marcelina Radziszewska et al.. Nutrients. 2022. Nutrition and Supplementation in Ulcerative Colitis. doi:10.3390/nu14122469 PubMed
- [11] Verônica Assalin Zorgetto-Pinheiro et al.. J Med Food. 2022. Omega-3 Fatty Acids and Balanced Gut Microbiota on Chronic Inflammatory Diseases: A Close Look at Ulcerative Colitis and Rheumatoid Arthritis … doi:10.1089/jmf.2021.0012 PubMed
- [12] Vishnu Kalladathvalappil Venugopalan et al.. Foods. 2021. Encapsulation and Protection of Omega-3-Rich Fish Oils Using Food-Grade Delivery Systems. doi:10.3390/foods10071566 PubMed
- [13] Jean-Frédéric LeBlanc et al.. Nutrients. 2021. The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis. doi:10.3390/nu13061780 PubMed
- [14] Robert Carreras-Torres et al.. Sci Rep. 2020. Identifying environmental risk factors for inflammatory bowel diseases: a Mendelian randomization study. doi:10.1038/s41598-020-76361-2 PubMed
- [15] Sherman Picardo et al.. Therap Adv Gastroenterol. 2020. Complementary and alternative medications in the management of inflammatory bowel disease. doi:10.1177/1756284820927550 PubMed
- [16] Mohita Sharma et al.. Toxicol Mech Methods. 2019. Redox modulatory protective effects of ω-3 fatty acids rich fish oil against experimental colitis. doi:10.1080/15376516.2018.1553220 PubMed
- [17] Masako Nakanishi et al.. Nutrients. 2019. Dietary Walnut Supplementation Alters Mucosal Metabolite Profiles During DSS-Induced Colonic Ulceration. doi:10.3390/nu11051118 PubMed
- [18] Berkeley N Limketkai et al.. Gastroenterol Clin North Am. 2018. Nutritional Interventions in the Patient with Inflammatory Bowel Disease. doi:10.1016/j.gtc.2017.09.007 PubMed
- [19] Eleonora Scaioli et al.. Int J Mol Sci. 2017. The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives. doi:10.3390/ijms18122619 PubMed
- [20] Islam Khan et al.. Med Princ Pract. 2017. Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal. doi:10.1159/000468988 PubMed
- [21] Christian Lodberg Hvas et al.. Ugeskr Laeger. 2017. [Nutrition and dietary supplement in chronic inflammatory bowel diesease]. PubMed
- [22] Sandra Maria Barbalho et al.. Ann Gastroenterol. 2016. Inflammatory bowel disease: can omega-3 fatty acids really help? PubMed
- [23] Raquel Cristina Schwanke et al.. Eur J Pharmacol. 2016. EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. doi:10.1016/j.ejphar.2015.08.050 PubMed
- [24] Alyssa Parian et al.. Curr Pharm Des. 2016. Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis. doi:10.2174/1381612822666151112145033 PubMed
- [25] Meagen McCusker et al.. Clin Dermatol. 2016. Nutrition and skin: Kids are not just little people. doi:10.1016/j.clindermatol.2016.07.004 PubMed
- [26] Suneela S Dhaneshwar. World J Gastroenterol. 2014. Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease. doi:10.3748/wjg.v20.i13.3564 PubMed
- [27] Affifa Farrukh et al.. World J Clin Cases. 2014. Is there a role for fish oil in inflammatory bowel disease? doi:10.12998/wjcc.v2.i7.250 PubMed
- [28] S C Ng et al.. Aliment Pharmacol Ther. 2013. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. doi:10.1111/apt.12464 PubMed
- [29] Mi-Kyung Sung et al.. World J Gastroenterol. 2013. Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view. doi:10.3748/wjg.v19.i7.994 PubMed
- [30] Eduard Cabré et al.. Br J Nutr. 2012. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. doi:10.1017/S0007114512001626 PubMed
- [31] Fiona J Bath-Hextall et al.. Cochrane Database Syst Rev. 2012. Dietary supplements for established atopic eczema. doi:10.1002/14651858.CD005205.pub3 PubMed
- [32] Eduard Cabré et al.. World J Gastroenterol. 2012. Impact of environmental and dietary factors on the course of inflammatory bowel disease. doi:10.3748/wjg.v18.i29.3814 PubMed
- [33] Melissa A Smith et al.. Frontline Gastroenterol. 2012. Nutritional management of adults with inflammatory bowel disease: practical lessons from the available evidence. doi:10.1136/flgastro-2011-100032 PubMed
- [34] Jason K Hou et al.. Am J Gastroenterol. 2011. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. doi:10.1038/ajg.2011.44 PubMed
- [35] Dan Turner et al.. Inflamm Bowel Dis. 2011. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. doi:10.1002/ibd.21374 PubMed
- [36] Gerard E Mullin. Nutr Clin Pract. 2011. Comment On: Maintenance of Remission in Inflammatory Bowel Disease Using Omega-3 Fatty Acids (Fish Oil): A Systematic Review and Meta-Analyses. doi:10.1177/0884533611400087 PubMed
- [37] Cinzia Papadia et al.. JRSM Short Rep. 2010. Omega-3 fatty acids in the maintenance of ulcerative colitis. doi:10.1258/shorts.2010.010004 PubMed
- [38] Hisayuki Matsunaga et al.. Inflamm Bowel Dis. 2008. Omega-3 fatty acids exacerbate DSS-induced colitis through decreased adiponectin in colonic subepithelial myofibroblasts. doi:10.1002/ibd.20491 PubMed
- [39] D Turner et al.. Cochrane Database Syst Rev. 2007. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. doi:10.1002/14651858.CD006443.pub2 PubMed
- [40] R Borneo et al.. J Food Sci. 2007. Stability and consumer acceptance of long-chain omega-3 fatty acids (eicosapentaenoic acid, 20:5, n-3 and docosahexaenoic acid, 22:6, n-3) in cream-filled … doi:10.1111/j.1750-3841.2006.00240.x PubMed
- [41] Décio Sabbatini Barbosa et al.. Nutrition. 2003. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. doi:10.1016/s0899-9007(03)00162-x PubMed
- [42] F G Campos et al.. Nutr Hosp. 2003. Pharmacological nutrition in inflammatory bowel diseases. PubMed
- [43] Artemis P Simopoulos. J Am Coll Nutr. 2002. Omega-3 fatty acids in inflammation and autoimmune diseases. doi:10.1080/07315724.2002.10719248 PubMed
- [44] I Dichi et al.. Nutrition. 2000. Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis. doi:10.1016/s0899-9007(99)00231-2 PubMed
- [45] A Heller et al.. Drugs. 1998. Lipid mediators in inflammatory disorders. doi:10.2165/00003495-199855040-00001 PubMed
- [46] Y Z Almallah et al.. Am J Gastroenterol. 1998. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. doi:10.1111/j.1572-0241.1998.229_a.x PubMed
- [47] A Burke et al.. Baillieres Clin Gastroenterol. 1997. Nutrition and ulcerative colitis. doi:10.1016/s0950-3528(97)90059-2 PubMed
- [48] M Bartels et al.. Langenbecks Arch Chir. 1995. [What is the role of nutrition in ulcerative colitis? A contribution to the current status of diet therapy in treatment … doi:10.1007/BF00184410 PubMed
- [49] A Aslan et al.. Am J Gastroenterol. 1992. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. PubMed
- [50] A P Simopoulos. Am J Clin Nutr. 1991. Omega-3 fatty acids in health and disease and in growth and development. doi:10.1093/ajcn/54.3.438 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.